ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Adalimumab

Also written as “adalimumab”, “MSB11022” and “M923”.

Its studies are mostly in Arthritis, Rheumatoid · Psoriasis · Crohn Disease · Colitis, Ulcerative · Hidradenitis Suppurativa, led by 17 companies.

Drug pageAdalimumab: every studyMany companies study it; this page follows only the 149 they lead. All 319 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 13, 2005149 company-led studies, 7 open or runningNext primary completion: Jun 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Abbottits history only620 open or runningphase 4since Sep 13, 2005Nov 1, 2002none ahead
AbbVieits history only543 open or runningphase 4since May 25, 2010Sep 13, 2005Sep 2027phase 2 · NCT06257875
Alvotech Swissits history only60 open or runningphase 3since Feb 5, 2019Jun 8, 2018none ahead
Johnson & Johnsonits history only50 open or runningphase 3since Dec 18, 2013Dec 18, 2013none ahead
Fresenius Kabiits history only40 open or runningphase 3since Jan 17, 2016Jan 17, 2016none ahead
Biocadits history only30 open or runningphase 3since Mar 31, 2016Mar 16, 2015none ahead
Cinnagenits history only20 open or runningphase 3since May 24, 2017May 24, 2017none ahead
Sino Biopharmaceutical22 open or runningphase 4since Apr 8, 2026Apr 8, 2026Apr 2028phase 4 · NCT07529925
Takedaits history only20 open or runningphase 4since May 5, 2016Mar 15, 2015none ahead
Viatrisits history only20 open or runningphase 3since Nov 9, 2015Jun 3, 2015none ahead

Also a collaborator on its studies: Merck KGaA, Darmstadt, Germany, Mylan, Pharm-Olam, PPD DEVELOPMENT, LP, PRA Health Sciences, IST GmbH, Germany, Parexel, Pivotal S.L., GlaxoSmithKline, Regeneron Pharmaceuticals, Eisai and Abbott Japan.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sino Biopharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2017Named adalimumabINNProposed as its International Nonproprietary Name in WHO's List 118 · before, MSB11022, M923
  2. Apr 8, 2026First studies: 2 phase 4 studiesFirst studyNCT07529925, NCT07564505

Ahead

  1. Apr 2028Primary completion: phase 4 study in Severe Plaque Psoriasis in Chinese ChildrenNCT07529925
  2. Mar 2029Primary completion: phase 4 study in Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's DiseaseNCT07564505

TargetBeta

TNF →read by rule
“TNF-alpha inhibitor”ChEMBL 37, by rule

Other programs on TNF

ProgramCompanyFurthest phaseStudies
Brentuximab VedotinrulePfizerphase 437
CHS-1420rulenanjing-king-friend-biochemical-pharmaceutical-co-ltdphase 32
brivekimigSanofiphase 26
Hadlimarulebiora-therapeutics-incphase 11

Studies

All 2 Sino Biopharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07564505Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease · China4RecruitingMar 202930
NCT07529925Severe Plaque Psoriasis in Chinese Children4Not yet recruitingApr 202830

How it is read

Names in the registry

  • “Adalimumab”, 69 entries
  • “adalimumab”, 63 entries
  • “MSB11022”, 3 entries
  • “M923”, 3 entries
  • “Humira (adalimumab)”, 3 entries

Codes read as this program: AVT02.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.